Pharmacist Medication Insights: Viloxazine for Attention-Deficit Hyperactivity Disorder

Vviloxazine (Qelbree) is a norepinephrine reuptake inhibitor that provides a new treatment option for patients aged 6 to 17 years with ADHD.

Vviloxazine (Qelbree), is a new treatment option for attention-deficit hyperactivity disorder (ADHD), approved in the United States in April 2021. This drug is a norepinephrine reuptake inhibitor indicated for patients aged 6 to 17 years with ADHD.

It is taken once a day, with or without food. It may cause drowsiness, so these patients should not operate heavy machinery while taking this medication, until they know how they will react. Viloxazine can cause decreased appetite, irritability, nausea, tiredness, trouble sleeping, and vomiting.

It is available in dosages of 100, 150, and 200mg. Finally, concomitant use of this drug with monoamine oxidase inhibitors and cytochrome P450 1A2 substrates are contraindicated.

Related Videos
Senior Male Research Scientist is Using a Tablet Computer in a Modern High-Tech Laboratory. Genetics and Pharmaceutical Studies and Researches | Image Credit: Gorodenkoff -
Acute psoriasis on the elbows is an autoimmune incurable dermatological skin disease. Large red, inflamed, flaky rash on the knees. Joints affected by psoriatic arthritis | Image Credit: SNAB -
Portrait of a smiling female pharmacist, male colleague working with drugs in the background. | Image Credit: bnenin -
Dermatologist examining the skin of a patient | Image Credit: thodonal -
Burnout illustration | Image credit: Vikky Mir -
Public Health Matters podcast logo
© 2023 MJH Life Sciences

All rights reserved.